Improved Therapy for Hemophilia and Hereditary Bleeding Disorders

The summary for the Improved Therapy for Hemophilia and Hereditary Bleeding Disorders grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Improved Therapy for Hemophilia and Hereditary Bleeding Disorders: The National Heart, Lung, and Blood Institute (NHLBI) and the National Hemophilia Foundation (NHF) invite applications for studies that will lead to improved treatment of hemophilia, von Willebrand disease, and other hereditary bleeding disorders with the ultimate goal of finding a cure for bleeding disorders. The objectives of this program are to stimulate research to improve therapy, and enhance understanding of immune response and safety issues related to novel therapeutics, gene transfer or cell based therapies for bleeding disorders.

Federal Grant Title:	Improved Therapy for Hemophilia and Hereditary Bleeding Disorders
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-04-032
Type of Funding:	Grant
CFDA Numbers:	93.839
CFDA Descriptions:	Blood Diseases and Resources Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Jan 14, 2020
Posted Date:	Jun 21, 2004
Creation Date:	Jan 04, 2008
Archive Date:	Jan 15, 2005
Total Program Funding:
Maximum Federal Grant Award:	$250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Special district governments City or township governments Private institutions of higher education For profit organizations other than small businesses State governments Small businesses Public and State controlled institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments)
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immu...; • New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional); • Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...; • Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional); • Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional); • Clinical Hematology Research Career Development Program (K12); • Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...; • Specialized Centers of Clinically Oriented Research (Sccor) in Transfusion Biology and Med...
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...